Neosense Technologies AB
Neosense Technologies is an innovative Swedish medtech start-up based in Stockholm. We develop and supply advanced continuous oxygen monitoring systems designed for intensive care units, enabling improved patient safety and more precise clinical decision-making.
Neonatal Care
Extremely preterm infants require advanced intensive care due to underdeveloped organs and an immature immune system. Insufficient pulmonary function often necessitates supplemental oxygen and ventilatory support.
Excess oxygen levels increase the risk of retinopathy and eye damage, while insufficient oxygen raises the risk of severe organ injury and mortality. Therefore, maintaining blood oxygenation within very narrow limits is critical to reduce both acute and long-term complications. Current monitoring methods are not sufficient to ensure this level of precision.
Real-time access to blood oxygenation enables more accurate oxygen therapy for preterm infants. This advancement is expected to lower the incidence of permanent complications and mortality, a view strongly supported by leading experts in neonatology.
Technology
Neosense Technologies has developed a unique, first-in-class sensor for real-time measurement of blood oxygen tension. In intensive care, continuous monitoring and precise control of oxygenation within safe limits are essential to minimize the risk of serious complications.
Neosense offers healthcare providers worldwide an advanced solution with exceptional capability for real-time measurement, monitoring, and control of blood oxygenation in critically ill patients — enabling safer treatment and improved clinical outcomes.
